Ken Griffin Amicus Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.55 - $12.09 $237,795 - $301,041	24,900 Added 105.06%	48,600 $519,000
Q2 2024 Aug 14, 2024	SELL	$9.04 - $11.75 $9,040 - $11,750	-1,000 Reduced 4.05%	23,700 $235,000
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $59,436 - $74,048	-5,200 Reduced 17.39%	24,700 $290,000
Q4 2023 Feb 14, 2024	SELL	$9.97 - $14.52 $180,457 - $262,812	-18,100 Reduced 37.71%	29,900 $424,000
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $193,192 - $227,304	16,400 Added 51.9%	48,000 $583,000
Q2 2023 Aug 14, 2023	SELL	$10.72 - $13.3 $43,952 - $54,530	-4,100 Reduced 11.48%	31,600 $396,000
Q1 2023 May 15, 2023	SELL	$10.91 - $13.54 $712,423 - $884,162	-65,300 Reduced 64.65%	35,700 $395,000
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $604,279 - $775,970	61,100 Added 153.13%	101,000 $1.23 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $44,190 - $57,375	-4,500 Reduced 10.14%	39,900 $417,000

312

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.75B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.